These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

252 related items for PubMed ID: 11051265

  • 21. Preferential induction of apoptosis by interferon (IFN)-beta compared with IFN-alpha2: correlation with TRAIL/Apo2L induction in melanoma cell lines.
    Chawla-Sarkar M, Leaman DW, Borden EC.
    Clin Cancer Res; 2001 Jun; 7(6):1821-31. PubMed ID: 11410525
    [Abstract] [Full Text] [Related]

  • 22. Adriamycin sensitizes the adriamycin-resistant 8226/Dox40 human multiple myeloma cells to Apo2L/tumor necrosis factor-related apoptosis-inducing ligand-mediated (TRAIL) apoptosis.
    Jazirehi AR, Ng CP, Gan XH, Schiller G, Bonavida B.
    Clin Cancer Res; 2001 Dec; 7(12):3874-83. PubMed ID: 11751478
    [Abstract] [Full Text] [Related]

  • 23. Sensitivity of prostate cells to TRAIL-induced apoptosis increases with tumor progression: DR5 and caspase 8 are key players.
    Hesry V, Piquet-Pellorce C, Travert M, Donaghy L, Jégou B, Patard JJ, Guillaudeux T.
    Prostate; 2006 Jun 15; 66(9):987-95. PubMed ID: 16541419
    [Abstract] [Full Text] [Related]

  • 24. Synergistic induction of apoptosis in neuroblastoma cells using a combination of cytostatic drugs with interferon-gamma and TRAIL.
    Johnsen JI, Pettersen I, Ponthan F, Sveinbjørnsson B, Flaegstad T, Kogner P.
    Int J Oncol; 2004 Dec 15; 25(6):1849-57. PubMed ID: 15547726
    [Abstract] [Full Text] [Related]

  • 25. Trichostatin A sensitizes TRAIL-resistant myeloma cells by downregulation of the antiapoptotic Bcl-2 proteins.
    Fandy TE, Srivastava RK.
    Cancer Chemother Pharmacol; 2006 Oct 15; 58(4):471-7. PubMed ID: 16435155
    [Abstract] [Full Text] [Related]

  • 26. Subtoxic concentration of doxorubicin enhances TRAIL-induced apoptosis in human prostate cancer cell line LNCaP.
    Kang J, Bu J, Hao Y, Chen F.
    Prostate Cancer Prostatic Dis; 2005 Oct 15; 8(3):274-9. PubMed ID: 15897917
    [Abstract] [Full Text] [Related]

  • 27. Mechanisms of resistance to TRAIL-induced apoptosis in cancer.
    Zhang L, Fang B.
    Cancer Gene Ther; 2005 Mar 15; 12(3):228-37. PubMed ID: 15550937
    [Abstract] [Full Text] [Related]

  • 28. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and Fas apoptosis in Burkitt's lymphomas with loss of multiple pro-apoptotic proteins.
    Hussain A, Doucet JP, Gutiérrez M, Ahmad M, Al-Hussein K, Capello D, Gaidano G, Bhatia K.
    Haematologica; 2003 Feb 15; 88(2):167-75. PubMed ID: 12604406
    [Abstract] [Full Text] [Related]

  • 29. Augmentation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by the synthetic retinoid 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthalene carboxylic acid (CD437) through up-regulation of TRAIL receptors in human lung cancer cells.
    Sun SY, Yue P, Hong WK, Lotan R.
    Cancer Res; 2000 Dec 15; 60(24):7149-55. PubMed ID: 11156424
    [Abstract] [Full Text] [Related]

  • 30. Imatinib enhances human melanoma cell susceptibility to TRAIL-induced cell death: Relationship to Bcl-2 family and caspase activation.
    Hamaï A, Richon C, Meslin F, Faure F, Kauffmann A, Lecluse Y, Jalil A, Larue L, Avril MF, Chouaib S, Mehrpour M.
    Oncogene; 2006 Dec 07; 25(58):7618-34. PubMed ID: 16983347
    [Abstract] [Full Text] [Related]

  • 31. Potential mechanism of resistance to TRAIL-induced apoptosis in Burkitt's lymphoma.
    Tafuku S, Matsuda T, Kawakami H, Tomita M, Yagita H, Mori N.
    Eur J Haematol; 2006 Jan 07; 76(1):64-74. PubMed ID: 16343273
    [Abstract] [Full Text] [Related]

  • 32. Involvement of proapoptotic molecules Bax and Bak in tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced mitochondrial disruption and apoptosis: differential regulation of cytochrome c and Smac/DIABLO release.
    Kandasamy K, Srinivasula SM, Alnemri ES, Thompson CB, Korsmeyer SJ, Bryant JL, Srivastava RK.
    Cancer Res; 2003 Apr 01; 63(7):1712-21. PubMed ID: 12670926
    [Abstract] [Full Text] [Related]

  • 33. Rituximab modifies the cisplatin-mitochondrial signaling pathway, resulting in apoptosis in cisplatin-resistant non-Hodgkin's lymphoma.
    Alas S, Ng CP, Bonavida B.
    Clin Cancer Res; 2002 Mar 01; 8(3):836-45. PubMed ID: 11895917
    [Abstract] [Full Text] [Related]

  • 34. Direct stimulation of apoptotic signaling by soluble Apo2l/tumor necrosis factor-related apoptosis-inducing ligand leads to selective killing of glioma cells.
    Pollack IF, Erff M, Ashkenazi A.
    Clin Cancer Res; 2001 May 01; 7(5):1362-9. PubMed ID: 11350907
    [Abstract] [Full Text] [Related]

  • 35. Defining characteristics of Types I and II apoptotic cells in response to TRAIL.
    Ozören N, El-Deiry WS.
    Neoplasia; 2002 May 01; 4(6):551-7. PubMed ID: 12407450
    [Abstract] [Full Text] [Related]

  • 36. Sensitization of tumor cells to Apo2 ligand/TRAIL-induced apoptosis by inhibition of casein kinase II.
    Ravi R, Bedi A.
    Cancer Res; 2002 Aug 01; 62(15):4180-5. PubMed ID: 12154014
    [Abstract] [Full Text] [Related]

  • 37. Anticancer agents sensitize tumor cells to tumor necrosis factor-related apoptosis-inducing ligand-mediated caspase-8 activation and apoptosis.
    Lacour S, Hammann A, Wotawa A, Corcos L, Solary E, Dimanche-Boitrel MT.
    Cancer Res; 2001 Feb 15; 61(4):1645-51. PubMed ID: 11245478
    [Abstract] [Full Text] [Related]

  • 38. Intracellular mechanisms mediating tocotrienol-induced apoptosis in neoplastic mammary epithelial cells.
    Sylvester PW, Shah S.
    Asia Pac J Clin Nutr; 2005 Feb 15; 14(4):366-73. PubMed ID: 16326643
    [Abstract] [Full Text] [Related]

  • 39. Mechanisms involved in development of resistance to adenovirus-mediated proapoptotic gene therapy in DLD1 human colon cancer cell line.
    Zhang L, Gu J, Lin T, Huang X, Roth JA, Fang B.
    Gene Ther; 2002 Sep 15; 9(18):1262-70. PubMed ID: 12215894
    [Abstract] [Full Text] [Related]

  • 40. Frontline: Induction of apoptosis and modulation of c-FLIPL and p53 in immature dendritic cells infected with herpes simplex virus.
    Müller DB, Raftery MJ, Kather A, Giese T, Schönrich G.
    Eur J Immunol; 2004 Apr 15; 34(4):941-51. PubMed ID: 15048704
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.